Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Assets (2021 - 2025)

Historic Current Assets for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $10.8 million.

  • InMed Pharmaceuticals' Current Assets rose 4835.34% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 4835.34%. This contributed to the annual value of $12.9 million for FY2025, which is 4807.7% up from last year.
  • InMed Pharmaceuticals' Current Assets amounted to $10.8 million in Q3 2025, which was up 4835.34% from $12.9 million recorded in Q2 2025.
  • InMed Pharmaceuticals' Current Assets' 5-year high stood at $16.0 million during Q3 2021, with a 5-year trough of $5.5 million in Q4 2024.
  • For the 5-year period, InMed Pharmaceuticals' Current Assets averaged around $10.4 million, with its median value being $10.8 million (2025).
  • Per our database at Business Quant, InMed Pharmaceuticals' Current Assets crashed by 5368.26% in 2024 and then skyrocketed by 4835.34% in 2025.
  • InMed Pharmaceuticals' Current Assets (Quarter) stood at $12.5 million in 2021, then grew by 12.1% to $14.0 million in 2022, then fell by 15.75% to $11.8 million in 2023, then tumbled by 53.68% to $5.5 million in 2024, then skyrocketed by 97.44% to $10.8 million in 2025.
  • Its Current Assets stands at $10.8 million for Q3 2025, versus $12.9 million for Q2 2025 and $6.4 million for Q1 2025.